XML 44 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense By Award Type The following table summarizes stock-based compensation expense recognized for the years presented below (in thousands):
Year Ended December 31,
20242023
Restricted stock units$16,081 $19,151 
Performance-based stock units2,397 2,422 
Common stock options1,283 1,254 
Employee stock purchase program120 386 
Total stock-based compensation expense$19,881 $23,213 
Related tax benefit recognized$4,748 $5,488 
Schedule of Stock-Based Compensation Expense By Operating Function
The following table summarizes stock-based compensation expense by operating function for the years presented below (in thousands):
 Year Ended December 31,
 20242023
Marketing and advertising$2,413 $2,201 
Customer care and enrollment1,845 2,287 
Technology and content3,331 4,498 
General and administrative12,292 14,227 
Total stock-based compensation expense19,881 23,213 
Amount capitalized for internal-use software687 1,040 
Total stock-based compensation$20,568 $24,253 
Schedule of Activity Under Stock Plans The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data):
 
Number of Stock Options (1)
Weighted Average Exercise PriceWeighted-Average Remaining Contractual Life (years)
Aggregate Intrinsic Value (2)
Outstanding as of December 31, 2023218 $39.65 4.5$— 
Granted— $— 
Exercised— $— 
Forfeited(5)$18.75 
Outstanding balance as of December 31, 2024213 $40.15 3.6$— 
Exercisable as of December 31, 202494 $39.04 3.3$— 
_______ 
(1)Includes certain stock options with service, performance-based or market-based vesting criteria.
(2)The aggregate intrinsic value is calculated as the product between eHealth’s closing stock price as of December 31, 2024 and 2023 and the exercise price of in-the-money options as of those dates.
Schedule of Restricted Stock Unit Activity Under Stock Plans The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining service period data):
Number of Restricted Stock Units
Weighted-Average Grant Date Fair Value
Weighted-Average Remaining Service Period (years)
Aggregate Intrinsic Value (1)
Outstanding as of December 31, 20233,105 $11.31 1.3$27,083 
Granted1,921 $5.28 
Vested(1,384)$13.12 
Forfeited(531)$7.68 
Outstanding as of December 31, 20243,111 $7.41 1.1$29,247 
_______
(1)The aggregate intrinsic value is calculated as the difference of the grant date price and our closing stock price as of December 31, 2024 and 2023 multiplied by the number of restricted stock units outstanding as of December 31, 2024 and 2023, respectively.
Schedule of Performance-Based Stock Units The following table summarizes performance-based stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining service period data):
Number of Performance-based Stock Units
Weighted-Average Grant Date Fair Value
Weighted-Average Remaining Service Period (years)
Aggregate Intrinsic Value (1)
Outstanding as of December 31, 2023400 $14.32 0.6$3,486 
Granted365 $5.17 
Vested(303)$7.38 
Forfeited(77)$14.75 
Outstanding as of December 31, 2024385 $11.03 2.0$3,617 
_______
(1)The aggregate intrinsic value is calculated as the difference of the grant date price and our closing stock price as of December 31, 2024 and 2023 multiplied by the number of performance stock units outstanding as of December 31, 2024 and 2023, respectively.
Schedule of Restricted Stock Units, Valuation Assumptions
The weighted-average fair value of the market-based performance-based stock units was determined using the Monte Carlo simulation model using the following weighted average assumptions:
Year Ended December 31,
 20242023
Expected term (years)n/a1.1
Expected volatilityn/a76.3%
Expected dividend yieldn/a—%
Risk-free interest raten/a4.0%
Weighted-average grant date fair valuen/a$4.79